Participants were reported as genetically tested for BRCA1/2 (breast and ovarian cancer), MLH1, MSH2, MSH6, PMS2, or EPCAM (Lynch syndrome), and LDLR, APOB, or PCSK9 (FH). This evidence concerns the gene MSH6 and Lynch syndrome.